Bullish Stocks That Have Gained Most Year To Date Gainers: $RH $DARE $STSA

The Market Signal was created as a platform to help investors, if you own (NYSE:RH), (NASDAQ:DARE) or (NASDAQ:STSA) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW

(Click link above or copy, paste and hit enter in your browser for your report)

Restoration Hardware Holdings Topped Earnings Estimates In Q2 2020

https://themarketsignal.com/Free-Report/RH

(Click link above or copy, paste and hit enter in your browser for your report)

Restoration Hardware Holdings, Inc. (NYSE:RH) was up 50.39% year to date. The company's Q2 2020 earnings of $4.9 per share topped Zacks Consensus Estimates of $3.44 per share. the earnings rep[resents a surprise of 42.44% considering a quarter ago the company was expected to post earnings of $0.8 but posted earnings of $1.27 per share.

Revenue in the quarter ended July 2020 was $709.69 million surpassing estimates by 2.12%. In Q2 2019 the company posted revenue of $706.51 million. The current Zacks Consensus earnings estimate its $3.3 per share on revenue of $730.88 for the coming quarter and earnings of $11.91 per share for the current fiscal year in revenue of $2.61 billion.

Dare Bioscience Enters Product development Agreement With Avomeen

https://themarketsignal.com/Free-Report/DARE

(Click link above or copy, paste and hit enter in your browser for your report)

Dare Bioscience Inc. (NASDAQ:DARE) is also another bullish stock that is up 26.83% year to date. The company has entered a partnership agreement with Avomeen to accelerate the development of its novel pipeline of women's health programs. Under the agreement, Avomeen will offer contract product development services with a team assembled to advance development Dare's innovative investigational pipeline of products designed to meet unmet health needs in women.

Also, the company has published a proof of concept DARE-BV1 study in the Journal of Clinical and Experimental Obstetrics & Gynaecology. DARE-BV1 is an investigational thermosetting bioadhesive hydrogel formulation that contains clindamycin phosphate 2% currently being studied as a one-time vaginal administration for the treatment of patients with vaginosis.

Satsuma Pharmaceuticals Post Net Loss of $11.3 million in Q2 2020

https://themarketsignal.com/Free-Report/STSA

(Click link above or copy, paste and hit enter in your browser for your report)

Another stock that has surged year to date is Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) which is up 18.60%. The company reported a net loss of $11.3 million or $0.65 per share in Q2 2020 compared to a net loss of $6.3 million or $5.48 per share in Q2 2019. At the end of the quarter, the company has cash and cash equivalents of $93.7 million.

The company has announced topline data from the EMERGE third phase trial of STS101 in the treatment of acute migraine. STS101 was tolerated well in the trial and had low adverse effects with no serious adverse effects reported. The results did not show statistically significant differences between placebo and dosage strength of STS101 on primary endpoints of pain and the most bothersome symptom at two hours after administration.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_371120429/2705/2020-09-11T06:18:05

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.